Stocks · News reference
B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8
B of A Securities analyst Alec Stranahan initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Buy rating and announces Price Target of $8.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 20, 2026, 12:03 PM
- Checked
- Aug 20, 2026, 12:03 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures mixed, Nasdaq 100 up 0.1%. Coty Inc (COTY) shares down 7.7% after reporting losses in Q4 and exit of Gucci Beauty license.
Read original at benzingaProQR Therapeutics Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $10.183M Beat $5.560M Estimate
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 25 percent increase over losses of $(0.12) per share from
Read original at benzinga